107P - Efficacy and safety of erlotinib in elderly patients with lung cancer adenocarcinoma

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Non-Small-Cell Lung Cancer, Metastatic
Presenter Konstantinos Syrigos
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors K.N. Syrigos, P. Boura, D. Vassos, A. Vassias, A. Bastas, A. Boufas, I. Gkiozos
  • Oncology Unit Gpp, Sotiria General Hospital, Athens School of Medicine, 115 27 - Athens/GR


Besides chemotherapy, Erlotinib is another option in NSCLC patients especially in those with EGFR mutations. Elderly patients enrolled in trials are fit without co-morbidities, but in clinical practice most suffer from co-morbidities.